Phreesia (PHR) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
8 Jul, 2026Executive summary
Achieved positive free cash flow for the first time as a public company, marking a significant milestone in financial evolution and a new era of internally funded growth.
Q2 FY25 revenue grew 19% year-over-year to $102.1 million, with net loss narrowing to $18.0 million from $36.8 million and Adjusted EBITDA turning positive at $6.5 million from negative $11.5 million.
Operating cash flow was $11.1 million, up from negative $9.3 million in the prior year.
Free cash flow improved to $3.7 million, up from negative $15.2 million year-over-year.
Fiscal Q2 results were strong across key financial and operating metrics, supporting confidence in executing the full-year plan and continued profitable growth.
Financial highlights
Q2 FY25 total revenue reached $102.1 million, up 19% year-over-year; subscription and related services contributed $48.6 million, payment processing $25.3 million, and network solutions $28.2 million.
Net loss narrowed to $18.0 million, improved from $36.8 million year-over-year; net loss per share was $0.31, improved from $0.68.
Adjusted EBITDA was $6.5 million, up from negative $11.5 million year-over-year.
Free cash flow was $3.7 million, up from negative $15.2 million year-over-year.
Cash and cash equivalents were $81.8 million as of July 31, 2024.
Outlook and guidance
Fiscal 2025 revenue guidance maintained at $416–$426 million, representing 17–20% year-over-year growth.
Adjusted EBITDA guidance for FY25 raised to $26–$31 million from $21–$26 million.
AHSCs expected to reach ~4,200 in FY25 and ~4,500 in FY26.
Total revenue per AHSC expected to increase in FY25 and FY26.
Management believes cash and equivalents, along with normal business cash flow and available credit, are sufficient to fund operations for at least the next 12 months.
Latest events from Phreesia
- All proposals, including director elections and auditor ratification, were approved by stockholders.PHR
AGM 202630 Jun 2026 - Q1 FY2027 revenue up 13%, net income $3M, and FY2027 guidance reaffirmed.PHR
Q1 202728 May 2026 - Proxy seeks approval for director elections, auditor ratification, and executive pay, highlighting governance and ESG.PHR
Proxy filing14 May 2026 - Key votes include director elections, auditor ratification, and executive pay approval.PHR
Proxy filing14 May 2026 - FY27 revenue guidance lowered on pharma headwinds, but margin and cash flow outlooks remain strong.PHR
Q4 202630 Mar 2026 - Revenue up 17%, net loss narrowed, and Adjusted EBITDA positive with strong outlooks ahead.PHR
Q3 202511 Jan 2026 - Double-digit revenue growth, positive cash flow, and strong 2026 outlook maintained.PHR
Q4 202526 Dec 2025 - Q3 FY2026 saw 13% revenue growth, profitability, and a major acquisition completed.PHR
Q3 20269 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with focus on governance and ESG.PHR
Proxy Filing1 Dec 2025